(Total Views: 369)
Posted On: 07/02/2025 2:34:48 PM
Post# of 154898
News
Article
July 1, 2025
Leronlimab Shows Activity in Advanced Metastatic Colorectal Cancer
Jul 1, 2025
By Spencer Feldman
Fact checked by: Ryan Scott
Final results indicate that three out of five patients treated with leronlimab had at least a partial response, including one patient with a complete response who remains alive five years later, for patients with advanced metastatic colorectal cancer (mCRC) previously treated with leronlimab, according to a news release from CytoDyn.
Leronlimab is a CCR5 antagonist with the potential for multiple therapeutic indications. Associate professor at Georgetown University and lead researcher for CytoDyn’s colorectal cancer program, Dr. Benjamin Weinberg, will present clinical findings at the ESMO Gastrointestinal Cancers Congress 2025, held July 2 to 5 in Barcelona, Spain.
the basis for our belief in the potential of leronlimab as a treatment in CCR5 positive solid tumor oncology,” Dr. Jacob Lalezari, CEO of CytoDyn, said in the news release. “Our ongoing phase 2 trial in patients with mCRC was designed to prospectively confirm these observations, and we look forward to enrolling additional patients as we pursue clinical confirmation of our working theory
Source and read in full
https://www.curetoday.com/view/leronlimab-sho...tal-cancer
Article
July 1, 2025
Leronlimab Shows Activity in Advanced Metastatic Colorectal Cancer
Jul 1, 2025
By Spencer Feldman
Fact checked by: Ryan Scott
Final results indicate that three out of five patients treated with leronlimab had at least a partial response, including one patient with a complete response who remains alive five years later, for patients with advanced metastatic colorectal cancer (mCRC) previously treated with leronlimab, according to a news release from CytoDyn.
Leronlimab is a CCR5 antagonist with the potential for multiple therapeutic indications. Associate professor at Georgetown University and lead researcher for CytoDyn’s colorectal cancer program, Dr. Benjamin Weinberg, will present clinical findings at the ESMO Gastrointestinal Cancers Congress 2025, held July 2 to 5 in Barcelona, Spain.
the basis for our belief in the potential of leronlimab as a treatment in CCR5 positive solid tumor oncology,” Dr. Jacob Lalezari, CEO of CytoDyn, said in the news release. “Our ongoing phase 2 trial in patients with mCRC was designed to prospectively confirm these observations, and we look forward to enrolling additional patients as we pursue clinical confirmation of our working theory
Source and read in full
https://www.curetoday.com/view/leronlimab-sho...tal-cancer
(1)
(0)
